Yarrow Bioscience Inc
YARWHealthcare|Biotechnology|US
$15.60
+2.00 (+14.71%)
DCF Value
$23.72
Tangible Book / Share
$25.71
Cash / Share
$26.72
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07682896 Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease | Graves' Disease | P2 | Recruiting | 232 | RCT, Double-blind | Experimental: YB-101, Placebo YB-101 |